A DMT, or disease-modifying therapy, is a medication that slows down multiple sclerosis by reducing the inflammation that causes relapses and nerve damage. Unlike treatments that manage MS symptoms (like pain or fatigue), DMTs target the underlying disease process itself. The goal is to prevent relapses, delay disability progression, and help people with MS stay active and maintain their quality of life for as long as possible. There are now more than 20 FDA-approved DMTs available, and they come in three forms: injections, pills, and IV infusions.
How DMTs Work
Multiple sclerosis happens when the immune system mistakenly attacks the protective coating around nerve fibers in the brain and spinal cord. DMTs work by dialing down or redirecting that immune attack, though each medication does it differently.
Some DMTs take a broad approach. Interferons, one of the earliest classes of MS medication available since the mid-1990s, reduce the ability of inflammatory cells to cross into the brain and shift the immune system toward a less aggressive state. Glatiramer acetate works by diverting certain immune cells away from attacking the nerve coating, essentially acting as a decoy.
Others are more targeted. One group of medications traps immune cells inside lymph nodes so they never reach the brain and spinal cord. These drugs can reduce circulating immune cells by 70 to 80 percent within the first month. Another group specifically eliminates B cells, a type of immune cell heavily involved in MS inflammation, while leaving other parts of the immune system intact. A third approach physically blocks immune cells from crossing the blood-brain barrier, the gateway between the bloodstream and the central nervous system.
Some of the strongest DMTs work by broadly depleting multiple types of immune cells, including B cells, T cells, and others, then allowing the immune system to rebuild in a less harmful way. These tend to produce the most dramatic effects but also carry the most significant risks.
The Three Delivery Methods
Injectable DMTs were the only option for years and remain widely used. This category includes interferons and glatiramer acetate, which are self-injected at home on schedules ranging from every other day to once every two weeks. Newer injectable options like ofatumumab are also self-administered at home, typically once a month.
Oral DMTs became available starting in 2013 and changed the treatment landscape for many people. Pills like fingolimod, teriflunomide, and dimethyl fumarate are taken daily. Other oral options, like cladribine, are taken in short courses over two years and then stopped, with the immune effects lasting well beyond the treatment period. People on oral DMTs are generally less likely to stop treatment compared to those on injections or infusions.
Infused DMTs are given through an IV at a clinic or infusion center. Ocrelizumab, one of the most commonly prescribed, is given every six months. Natalizumab is infused monthly. Alemtuzumab is given in two annual treatment courses and then typically not repeated. Infusions require more time commitment per visit but less frequent dosing overall.
How Effective DMTs Are
Not all DMTs are equally powerful. The earlier, more established medications (interferons and glatiramer acetate) typically reduce relapse rates by roughly 30 percent compared to no treatment. Higher-efficacy medications, including the B-cell-depleting therapies, natalizumab, and alemtuzumab, tend to reduce relapses more substantially and have shown stronger effects on disability progression.
Preventing relapses matters beyond just avoiding short-term flare-ups. Evidence suggests that keeping relapses under control may reduce long-term disability accumulation and lower the risk of transitioning to progressive MS, the stage where disability worsens more steadily regardless of relapses.
Escalation vs. Starting Strong
One of the biggest decisions in MS treatment is whether to start with a milder DMT and escalate if it doesn’t work, or begin with a high-efficacy therapy right away. The traditional approach has been escalation: start with a safer, lower-efficacy medication and switch to something stronger only if you have breakthrough disease activity.
The alternative, sometimes called “early high-efficacy treatment,” means starting with a potent DMT from the outset. Modeling studies have found that certain high-efficacy treatment sequences produce more overall health benefit (measured in quality-adjusted life years) compared to escalation strategies, sometimes at similar cost-effectiveness. The trade-off is that stronger medications carry more serious potential side effects, so the decision depends heavily on how active your MS is at diagnosis, your age, your tolerance for risk, and your overall health.
For primary progressive MS specifically, the American Academy of Neurology recommends that clinicians offer ocrelizumab to people who are likely to benefit, as it is currently the only DMT approved for that form of the disease.
Common Side Effects by Class
Each category of DMT comes with its own side effect profile, and understanding what to expect can make a real difference in sticking with treatment.
- Interferons: Flu-like symptoms after injection are nearly universal in the first few months, including headache, fever, chills, and muscle aches. These typically improve over time. Injection site reactions and occasionally skin irritation can occur with forms injected under the skin.
- Glatiramer acetate: Generally well tolerated. Some people experience injection site reactions, and rarely a temporary episode of flushing, chest tightness, and anxiety that resolves on its own.
- Oral fumarates (dimethyl fumarate and related drugs): Flushing and gastrointestinal symptoms like diarrhea and nausea are the most common complaints, especially early on. These medications also reduce immune cell counts by 10 to 30 percent, mostly in the first year.
- Sphingosine-1-phosphate modulators (fingolimod, siponimod, ozanimod, ponesimod): The first dose can temporarily slow heart rate, so your first dose is monitored in a medical setting. Long-term, these drugs significantly lower circulating immune cells.
- Natalizumab: Infusion reactions (mainly headache, fatigue, dizziness) can occur within two hours of the infusion. The most serious concern is a rare but potentially fatal brain infection called progressive multifocal leukoencephalopathy, or PML, caused by reactivation of a common virus called JC virus.
- B-cell therapies (ocrelizumab, ofatumumab, ublituximab): Infusion or injection reactions are the most common side effect. Because these drugs suppress part of the immune system, infections are a concern over time.
- Alemtuzumab: Infusion reactions occur in over 90 percent of patients. Infections are common afterward (around 70 percent of patients), and new autoimmune conditions can develop up to five years after treatment.
Testing Before You Start
Before beginning any DMT, you’ll go through a round of screening blood work. The specifics depend on which medication you’re starting, but most require a complete blood count and a metabolic panel that checks liver and kidney function.
Many DMTs also require testing for JC virus antibodies. This is especially important for natalizumab, where JC virus status directly determines your risk of PML, but it’s also checked before starting fingolimod, dimethyl fumarate, ocrelizumab, and several others. If you’re starting a B-cell-depleting therapy, expect additional screening for tuberculosis, hepatitis B, hepatitis C, and immunoglobulin levels. Some medications also require a heart tracing (ECG) before the first dose, a chickenpox immunity check, or a skin exam.
Once on treatment, regular monitoring continues. Blood work is repeated at intervals to track immune cell counts, liver function, and other markers specific to your medication.
How Pregnancy Affects the Decision
Family planning is one of the most important factors in choosing a DMT, because MS disproportionately affects women of childbearing age. Experts recommend discussing pregnancy plans early and revisiting the topic regularly, since different medications have very different implications for conception timing.
The general guidance is to establish disease stability on a DMT for at least one year before attempting to conceive. Some medications need a washout period before pregnancy is safe, and that timeline varies widely. Certain therapies, like teriflunomide, carry a specific warning for birth defects and require a formal elimination procedure before conception.
Induction therapies and B-cell-depleting therapies offer a potential advantage here: their immune effects last much longer than the drug stays in the body. This means you can complete a treatment course, wait for the drug to clear your system, and still have some protective effect during pregnancy and the postpartum period, when relapse risk typically rises. Factors like age, the use of fertility treatments, and other health conditions also shape these decisions, making preconception planning with a neurologist essential.